More Support for Genetic Testing of Hepatitis C Patients

[Guest guest]

More Support for Genetic Testing of Hepatitis C Patients

A large retrospective study further confirms that the IL28B genotype predicts both early and sustained responses to interferon-based Hepatitis C treatment.

IL28B Genotype Predicts Treatment Response in Chronic Hepatitis C

By: MARY ANN MOON, Internal Medicine News Digital Network

Patients with treatment-naive chronic hepatitis C virus infection who carry the rs12979860 C/C or rs8099917 T/T polymorphisms in the region of the IL28B gene are more likely than are noncarriers to show an early virologic response, as well as a sustained virologic response, to interferon-based therapy, Dr. Albert Stättermayer and his colleagues reported in the April issue of Clinical Gastroenterology and Hepatology.

Currently, the IL28B status of patients is obtained routinely and is used to predict the likelihood of their response to combined peginterferon/ribavirin therapy.

Continue reading this entire article:http://www.internalmedicinenews.com/news/gastroenterology/single-article/il28b-genotype-predicts-treatment-response-in-chronic-hepatitis-c/ee1b70a539.html

http://www.hepatitis-central.com/mt/archives/2011/03/more_support_fo.html